Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations

Background: To determine the effectiveness of medroxyprogesterone acetate therapy for women with endometrial adenocarcinoma who wish to preserve their uterus.

Study design: Fifteen patients with endometrial carcinoma (12 with grade 1 endometrioid adenocarcinoma. 2 with grade 2 adenocarcinoma and 1 with adenoacanthoma) were treated with high-dose medroxyprogesterone acetate alone as primary therapy and their clinical responses evaluated.

Results: Seven of the 12 cases (58%) with grade I adenocarcinoma and one of the two (50%) with grade 2 carcinoma responded initially to medroxyprogesterone acetate. The median length of treatment required for regression was 29 weeks. Three patients who initially responded relapsed. Thirteen patients are alive without evidence of disease as of December 1999 (10 to 146 months, median; 4 years and 11 months) and one is continuing medroxyprogesterone acetate therapy as a final follow-up. One patient was lost to follow-up. Two patients have conceived having three healthy infants.

Conclusion: Treatment of endometrial carcinoma with high-dose medroxyprogesterone acetate could be an alternative to hysterectomy, although the successful rate is limited.

Endometrial carcinoma; Medroxyprogesterone acetate; Fertility

[1] Jobo T.: "Conservative therapy for gynecological malignant tumors (in Japanese)". Kanagawa Distr. J. Jpn Obstet. Gynecol. Soc., 1999, 35, 170.

[2] Jobo T., Ohkawara S.,T suchiya G.,K uramoto H.,A rai M.: "Chnicopathological analysis of endometrial carcinoma in young women (in Japanese with English abstract). J. Jpn Soc. Center Ther, 1989, 24, 2362.

[3] Quinn M.A.,K neale B. J., Fortune D. W.: "Endometrial carCJnoma in premenopausal women. A clinicopathological study". Gynecol. Oncol., 1985; 20, 298.

[4] Gallup D. G.,S tock R. J.: "Adenocarcinoma of the endometrium in women 40 years of age or younger". Obstet. Gynecol., 1984, 64, 417.

[5] Jobo T., Tateoka K., Kuramoto H.: "Study on the long-term follow-up of endometrial hyperplasia". Int. J. Clin. Oncol., 1996, I, 163.

[6] Kurman R. J.,K aminski P. F.,N orris H.J.: "The behavior of endometrial hyperplasia". Cancer, 1985, 56,403.

[7] DiSaia P. J.,C reasman W. T.: "Clinical Gynecologic Oncology" St. Louis, Mosby Year Book, 1993, 134.

[8] Randall T. C.,K urman R. J.: "Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40". Obstet. Gynecol., 1997, 90, 434.

[9] Hreshchhshyn M. M., Graham R. M.: " 17a - Hydroxyprogesterone caproate treatment of gynecologic cancer". Am. J. Obstet. Gynecol., 1969, 104, 916.

[10] Bokhman J. V.,C hepick 0. F., Volkova A. T., Vishnevsky A. S.: "Can primary endometrial carcinoma stage I be cured without surgery and radiati on therapy?". Gynecol. Oncol., 1985, 20, 139.

[11] Kim Y. B.,H olschneider C.H.,G hosh K..,N ieberg R. K., Montz F. J.: "Progestin alone as primary treatment of endometrial carcinoma in premenopausal women". Cancer, 1997, 79, 320.

[12] Scully R. E.,K urman R. J.,S ilverberg S. G.: "Histological typmg of female genital tract tumors". 2nd ed WHO International histological classification of tumors.

[13] Kottmeier H. L.: "Annual report on the results of treatment in gynecological cancer FIGO". Vol. 18,S tockholm, 1982.

[14] Kurihara S., Okada K.,A kiya K., Ozawa M.,K asamatu T.,K uramoto H. et al.: "Analysis of therapeutic effects of Medroxyprogesterone acetate (MPA) for endometrial adenocarcinoma (in Japanese)". Sannpu Jissai, 1985, 34, 517.

[15] Jobo T., Imai M., Kawaguchi M., Kenmochi M., Kuramoto H.: "Successful conservative treatment of endometrial carcinoma permitting subsequent pregnancy: report of two cases". Eur. J. Gynec Oncol., 2000, 21, 119.

[16] Thornton J. G.,B rown L.A.,W ells M.,S cott J. S.: " Primary treatment of endometrial cancer with progestogen alone". Lancet, 1985, 2, 207.

[17] Eddy W. A.: "Endometrial carcinoma in Stein-Leventhal syndrome treated with hydroxyprogesterone caproate". Am. J. Obstet Gynecol., 1978, 131, 581.

[18] NiwaK., Morishita S.,H ashimoto M., Yokoyama Y.,T amaya T.: "Conservative therapy for endometrial carcinoma in young women treated with repeated curettage and progestogen". Int. J. Clin. Oncol., 1997, 2, 165.

[19] Kimming R.,S trowitzki T.,M uller-Hocker J.,K urzl R.,K orell M., Hepp H.: "Case report. Conservative treatment of endometrial cancer permitting subcutaneous triplet pregnancy". Gynecol Oncol., 1995, 58, 255.